Evidence map›Paper›PMID 33168605›Full record

ArticleAntimicrobial agents and chemotherapy2021

Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.

Ana Motos, Gianluigi Li Bassi, Francesco Pagliara, Laia Fernandez-Barat, Hua Yang, Eli Aguilera Xiol, Tarek Senussi, Francesco A Idone, Chiara Travierso, Chiara Chiurazzi and 15 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 9 institutions in 4 countries.

Ana Motos *Division of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Gianluigi Li Bassi *Division of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Francesco PagliaraDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Laia Fernandez-BaratDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Hua YangDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Eli Aguilera XiolDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Tarek SenussiDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Francesco A IdoneDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Chiara TraviersoDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Chiara ChiurazziDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Rosanel AmaroDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Minlan YangDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Joaquim BobiDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Montserrat RigolDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
David P NicolauCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0000-0002-4148-0165
Gerard FrigolaDepartment of Pathology, Hospital Clinic, Barcelona, Spain.
Roberto CabreraDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain.
Jose RamirezDepartment of Pathology, Hospital Clinic, Barcelona, Spain.
Paolo PelosiDepartment of Surgical Sciences and Integrated Diagnostics (DISC), IRCCS AOU San Martino IST, Genoa, Italy.
Francesco BlasiFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy.
Massimo AntonelliDepartment of Anesthesiology, Intensive Care, and Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Antonio ArtigasAutonomous University of Barcelona, Department of Intensive Care Medecine, CIBER Enfermedades Respiratorias, Corporacion Sanitaria Universitaria Parc Tauli, Sabadell, Spain.
Jordi VilaMicrobiology Department, Hospital Clínic, CRESIB ISglobal, Barcelona, Spain.ORCID 0000-0002-8025-3926
Marin KollefDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Antoni TorresDivision of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain atorres@clinic.cat.ORCID 0000-0002-8643-2167
Hospital Clínic de Barcelona · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESUniversità Cattolica del Sacro Cuore · ITUniversity of Milan · ITHartford Hospital · USHumanitas University · ITOspedale Policlinico San Martino · ITUniversitat Autònoma de Barcelona · ESWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rising frequency of multidrug-resistant and extensively drug-resistant (MDR/XDR) pathogens is making more frequent the inappropriate empirical antimicrobial therapy (IEAT) in nosocomial pneumonia, which is associated with increased mortality. We aim to determine the short-term benefits of appropriate empirical antimicrobial treatment (AEAT) with ceftolozane/tazobactam (C/T) compared with IEAT with piperacillin/tazobactam (TZP) in MDR

Indexed as

Anti-Infective AgentsCross InfectionHealthcare-Associated PneumoniaPseudomonas InfectionsAnimalsAnti-Bacterial AgentsCephalosporinsDrug Resistance, Multiple, BacterialMicrobial Sensitivity TestsPenicillanic AcidPseudomonas aeruginosaSwineTazobactamAnti-Bacterial AgentsAnti-Infective AgentsceftolozaneCephalosporinsPenicillanic AcidTazobactamanimal modelsappropriate empirical antimicrobial treatmentmechanical ventilationpneumoniaPseudomonas aeruginosa

Identifiers

PMID33168605
PMCPMC7848990
OpenAlexW3095094289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.